- Home
- ARCO vs FTRE Comparison
ARCO vs FTRE Comparison
Compare ARCO & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARCO
- FTRE
- Stock Information
- Founded
- ARCO 2007
- FTRE 1996
- Country
- ARCO Uruguay
- FTRE United States
- Employees
- ARCO N/A
- FTRE N/A
- Industry
- ARCO Restaurants
- FTRE Medical Specialities
- Sector
- ARCO Consumer Discretionary
- FTRE Health Care
- Exchange
- ARCO Nasdaq
- FTRE Nasdaq
- Market Cap
- ARCO 1.8B
- FTRE 1.9B
- IPO Year
- ARCO 2011
- FTRE N/A
- Fundamental
- Price
- ARCO $7.29
- FTRE $18.70
- Analyst Decision
- ARCO Buy
- FTRE Hold
- Analyst Count
- ARCO 1
- FTRE 11
- Target Price
- ARCO $12.00
- FTRE $23.30
- AVG Volume (30 Days)
- ARCO 1.2M
- FTRE 890.4K
- Earning Date
- ARCO 03-12-2025
- FTRE 03-10-2025
- Dividend Yield
- ARCO 3.29%
- FTRE N/A
- EPS Growth
- ARCO N/A
- FTRE N/A
- EPS
- ARCO 0.69
- FTRE N/A
- Revenue
- ARCO $4,501,397,000.00
- FTRE $2,975,600,000.00
- Revenue This Year
- ARCO $5.31
- FTRE N/A
- Revenue Next Year
- ARCO $7.85
- FTRE $1.09
- P/E Ratio
- ARCO $10.36
- FTRE N/A
- Revenue Growth
- ARCO 7.82
- FTRE 2.80
- 52 Week Low
- ARCO $7.02
- FTRE $16.53
- 52 Week High
- ARCO $13.20
- FTRE $41.02
- Technical
- Relative Strength Index (RSI)
- ARCO 39.69
- FTRE 48.38
- Support Level
- ARCO $7.14
- FTRE $16.94
- Resistance Level
- ARCO $7.60
- FTRE $18.52
- Average True Range (ATR)
- ARCO 0.21
- FTRE 1.00
- MACD
- ARCO 0.02
- FTRE -0.02
- Stochastic Oscillator
- ARCO 38.28
- FTRE 53.01
About ARCO Arcos Dorados Holdings Inc. Shares
Arcos Dorados Holdings Inc operates McDonald's-branded restaurants in approximately 20 countries and territories in Latin America and the Caribbean. It functions through two sources which include company-operated restaurants and franchised restaurants segment. Their menu includes hamburgers, McNuggets, salad, sandwiches, french fries and others.
About FTRE Fortrea Holdings Inc.
Fortrea Holdings is a late-stage contract research organization, or CRO, that provides comprehensive Phase I through IV clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.